Cargando…

Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells

Several anti-cancer drugs are known to have immunomodulatory effects, including immunogenic cell death (ICD) of cancer cells. ICD is a form of apoptosis which is caused by the release of damage-associated molecular patterns (DAMPs), the uptake of cancer antigens by dendritic cells, and the activatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsushita, Maiko, Kashiwazaki, Sho, Kamiko, Satoshi, Kobori, Michio, Osada, Makoto, Kunieda, Hisako, Hirao, Maki, Ichikawa, Daiju, Hattori, Yutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609901/ https://www.ncbi.nlm.nih.gov/pubmed/37895838 http://dx.doi.org/10.3390/ph16101367

Ejemplares similares

GTN057, a komaroviquinone derivative, induced myeloma cells' death in vivo and inhibited c‐MET tyrosine kinase
por: Okayama, Mikio, et al.
Publicado: (2023)

Characteristics of a Novel Target Antigen against Myeloma Cells for Immunotherapy
por: Matsushita, Maiko, et al.
Publicado: (2020)

Negative E-cadherin expression on bone marrow myeloma cell membranes is associated with extramedullary disease
por: Hirao, Maki, et al.
Publicado: (2022)

A Novel Phthalimide Derivative, TC11, Has Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts
por: Matsushita, Maiko, et al.
Publicado: (2015)

Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents
por: Kurtin, Sandra E., et al.
Publicado: (2013)

Rare evolution of CSF3R-mutated chronic neutrophilic leukemia to t(4;12)(q12;p13) acute myeloid leukemia with SETBP1 mutation
por: Hirao, Maki, et al.
Publicado: (2022)

Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma
por: Domenger, Antoine, et al.
Publicado: (2023)

Identification of Novel HLA-A*24:02-Restricted Epitope Derived from a Homeobox Protein Expressed in Hematological Malignancies
por: Matsushita, Maiko, et al.
Publicado: (2016)

Monitoring of immunity against leukemia stem cell in CML patients after cessation of TKI
por: Matsushita, Maiko, et al.
Publicado: (2015)

Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy
por: Matsushita, Maiko, et al.
Publicado: (2018)

Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients
por: Oostvogels, Rimke, et al.
Publicado: (2018)

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib
por: Scirocchi, Fabio, et al.
Publicado: (2021)

Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors
por: Yalnız, Fevzi Fırat, et al.
Publicado: (2017)

Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022)

Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment
por: Clemens, Pamela L., et al.
Publicado: (2016)

Quantitative Phosphoproteomics of Proteasome Inhibition in Multiple Myeloma Cells
por: Ge, Feng, et al.
Publicado: (2010)

A myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor
por: Hattori, Y, et al.
Publicado: (2013)

Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high‐risk multiple myeloma in Asian patients
por: Byun, Ja Min, et al.
Publicado: (2018)

Proteasome Inhibitors for the Treatment of Multiple Myeloma
por: Ito, Shigeki
Publicado: (2020)

Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
por: Davda, Jasmine, et al.
Publicado: (2019)

Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Incidentally Detected by Fluorodeoxyglucose-positron Emission Tomography/Computed Tomography at a Health Checkup
por: Kunieda, Hisako, et al.
Publicado: (2022)

Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
por: Serrano-del Valle, Alfonso, et al.
Publicado: (2019)

New proteasome inhibitors in the treatment of multiple myeloma
por: Hungria, Vania Tietsche de Moraes, et al.
Publicado: (2019)

Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma
por: Patel, Urmeel H., et al.
Publicado: (2015)

Adherence to immunomodulatory drugs in patients with multiple myeloma
por: Cransac, Amélie, et al.
Publicado: (2019)

Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs
por: Takamatsu, Hiroyuki, et al.
Publicado: (2023)

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
por: Acosta-Alvear, Diego, et al.
Publicado: (2015)

The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors
por: Paul, Barry, et al.
Publicado: (2020)

Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells
por: WADA, NAOKO, et al.
Publicado: (2014)

Hypoxia-induced 26S proteasome dysfunction increases immunogenicity of mesenchymal stem cells
por: Abu-El-Rub, Ejlal, et al.
Publicado: (2019)

The Effects of Proteasome Inhibitors on Telomerase Activity and Regulation in Multiple Myeloma Cells
por: Shalem-Cohavi, Naama, et al.
Publicado: (2019)

Soluble and Cell–Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma
por: Farrell, Mariah L., et al.
Publicado: (2018)

Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
por: Maes, Ken, et al.
Publicado: (2019)

Proteasome inhibition and its therapeutic potential in multiple myeloma
por: Chari, Ajai, et al.
Publicado: (2010)

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
por: Merin, Noah M., et al.
Publicado: (2014)

Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
por: Ramirez, Krista G.
Publicado: (2017)

Proteasome inhibition: the dawn of novel therapies in multiple myeloma
por: Engelhardt, Monika, et al.
Publicado: (2022)

Immunogenicity and immunomodulatory effects of the human chondrocytes, hChonJ
por: Lim, Chae-Lyul, et al.
Publicado: (2017)

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
por: Chanan-Khan, A A, et al.
Publicado: (2013)

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
por: Gu, Yanyan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7e2hglmb6vb7d70s1hb8jis12c